Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also generate tubular MAU. The current observational study evaluated the impact of statin use on the interpretation of MAU as a predictor or marker of cardiovascular or renal disease.
We used cross-sectional data of ERICABEL, a cohort with 1,076 hypertensive patients. MAU was defined as albuminuria ≥20 mg/l. A propensity score was created to correct for “bias by indication” to receive a statin. As expected, subjects using statins vs. no statins had more cardiovascular risk factors, pointing to bias by indication. Statin users were more likely to have MAU (OR: 2.01, 95%CI: 1.34–3.01). The association between statin use and MAU remained significant after adjusting for the propensity to receive a statin based on cardiovascular risk factors (OR: 1.82, 95%CI: 1.14–2.91). Next to statin use, only diabetes (OR: 1.92, 95%CI: 1.00–3.66) and smoking (OR: 1.49, 95%CI: 0.99–2.26) were associated with MAU.
Use of statins is independently associated with MAU, even after adjusting for bias by indication to receive a statin. In the hypothesis that this MAU is of tubular origin, statin use can result in incorrect labeling of subjects as having a predictor or marker of cardiovascular or renal risk. In addition, statin use affected the association of established cardiovascular risk factors with MAU, blurring the interpretation of multivariable analyses.
Citation: van der Tol A, Van Biesen W, Van Laecke S, Bogaerts K, De Lombaert K, Warrinnier H, et al. (2012) Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study. PLoS ONE 7(2): e31639. https://doi.org/10.1371/journal.pone.0031639
Editor: James M. Wright, University of British Columbia, Canada
Received: September 16, 2011; Accepted: January 10, 2012; Published: February 16, 2012
Copyright: © 2012 van der Tol et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The funder of this study was F. Hoffmann-La Roche Ltd. The funder had a role in data collection because the ERICABEL study was initiated by F. Hoffmann-La Roche Ltd. The funder had no other role in the study design, analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have read the journal's policy and have the following conflicts: The authors Koen De Lombaert and Hans Warrinnier are employees of Hoffman-La Roche Ltd. The author Kris Bogaerts was appointed as a statistician by Hoffman La Roche Ltd. All the other authors have no conflict of interest to declare. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular morbidity and mortality, particularly in patients with other risk factors –, and as a surrogate for early kidney damage especially in subjects with diabetes and hypertension , . Statins are frequently prescribed in patients with hypertension, diabetes and metabolic syndrome, to reduce cardiovascular morbidity and mortality . Statins can reduce existent proteinuria – through a positive impact on endothelial dysfunction. In contrast, there is in vitro ,  and in vivo – evidence that statins are associated with de novo albuminuria and proteinuria. It is of importance to establish the association between statin use and MAU to correctly interpret presence of MAU as a predictor or marker of cardiovascular or renal disease in observational trials with a mixed population of subjects taking and not taking a statin. If statin use is associated with MAU, there is a risk of incorrect labeling of subjects as having a predictor or marker of cardiovascular or renal risk. The current study evaluated the association between statin use and MAU, and used a propensity score analysis to adjust for bias by indication. For this goal, we used the baseline data of the early renal impairment and cardiovascular assessment in Belgium (ERICABEL) trial, a prospective cohort of hypertensive patients followed by primary care physicians created to evaluate the impact of metabolic syndrome on cardiovascular and renal endpoints.
The primary aim of the ERICABEL study was to determine the effect of metabolic risk factors on the evolution of renal function and cardiovascular outcome over 5 years, in patients aged between 40 and 70 years with diagnosed hypertension, and followed by their primary care physician. The current analysis was designed to evaluate 1° the association between statin treatment and MAU and 2° the impact of statin treatment on the interpretation of the association between individual cardiovascular risk factors and MAU in epidemiological studies.
We used the baseline data of the ERICABEL cohort, a non-interventional epidemiological study with a follow up of 5 years that included 1,076 Caucasian patients with hypertension, defined as systolic blood pressure ≥140 mmHg and/or intake of at least one antihypertensive drug, recruited by 96 general practitioners, between 2006 and 2007, in Belgium. Of the 1076 patients included in this cross-sectional study, 420 patients had a missing value for at least one of the variables under investigation (see appendix table S1 for detailed list). Multiple imputation techniques were used to account for the missing data, using 20 imputations . All characteristics and outcome (MAU) were simultaneously used in the imputation model. The imputation was done using the R function aregImpute from the Hmisc package .
Description of procedures
Each participating primary care physician was asked to include 10 consecutive hypertensive patients aged between 40–70 years, in a 1∶1 sex ratio. The eligible persons were evaluated at baseline and if eligible, sociodemographic information (age, sex, race, and education level), personal and family medical history, smoking status and medication use were collected prospectively in an online database. Body weight was recorded to the nearest 0.1 Kg and height was measured to the nearest centimeter. Body mass index (BMI) was calculated as body weight in Kg divided by height2 (kg/m2). Blood pressure was measured according to the WHO criteria with a calibrated Omron HEM-907 device (average of 2 measurements, sitting, with 5 minutes in between). All these measurements were done by the primary care physician. After exclusion of a urinary infection or hematuria (negative Combur® test), MAU was screened by a Micral® dipstick test. MAU was considered present if measured albuminuria was ≥20 mg/l on a morning midstream urine sample. Blood sampling was performed by the general practitioner in fasting patients.
The metabolic syndrome was defined as three or more of the following criteria, according to the National Cholesterol Education Program Third Adult Treatment Panel guidelines ATP III criteria : elevated blood pressure >130/85 mmHg and/or antihypertensive medication (by definition 100% in this cohort), (2) high plasma triglycerides (>1.7 mmol/l), low HDL cholesterol (<1.0 mmol/l in men and <1.3 mmol/l in women), (4) abdominal adiposity (waist circumference >102/88 cm men/women) and/or impaired glucose tolerance (IGT) (fasting plasma glucose >6.1 mmol/l and/or known diabetes).
The study was approved by an independent ethics committee review board, protocol number: ML 19208. A written informed consent was obtained from all participants.
All analyses have been performed using SAS software (SAS software, version 9.2 of the SAS System for Windows. Copyright © 2002 SAS Institute Inc.) or R Version 2.12.0 (R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, 2009) . MAU was considered as a dichotomic variable. Continuous variables were described by their mean, standard deviation, median and interquartile range. Categorical variables were summarised by frequencies and percentages.
A propensity score for statin use was created to correct for “bias by indication”. Propensity score analysis is a well established method to adjust for confounding by indication in observational trials , . Primarily, for the statistical analyses, 20 imputed samples were created. In a second step, within each of the 20 samples separately, a propensity model was constructed and the resulting propensity score was calculated for each of these patients. The propensity model included the following variables that were deemed to be possibly related to statin use: age, gender, BMI, waist circumference, SBP, previous CV event, CRP, fasting glucose, diabetes, serum uric acid, HDL and LDL cholesterol, triglycerides, use of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACE-I/ARB) and smoking. Continuous variables in the model were included using restricted cubic splines: each continuous variable was included in the model using 3 dummy variables, called var1, var2 and var3. For the first 5 imputed samples, a histogram of the propensity scores was presented by statin use (see appendix table S2). In addition, in order to check the ability of the propensity scores to balance the two statin groups for baseline characteristics, tables were presented for the first 5 imputed samples, comparing the baseline characteristics between the groups (see appendix table S3). In this way, patients with the same “likelihood” or “propensity” to receive a statin (i.e. in this setting mainly with comparable cardiovascular risk factors), but in one case taking and in the other case not taking a statin, were compared for presence of MAU.
For comparison of continuous variables, ANOVA was used, adjusted for propensity scores, whereas for binary variables, logistic regression analyses, also adjusted for propensity scores, were employed. Logistic regression analyses were used to assess the association between statin use and MAU using the “GENMOD” procedure in SAS. The associations were assessed in each of the 20 imputation samples separately and the results were combined using the SAS procedure “MIANALYZE”. The following logistic regression models were used: 1°: Univariable model only including statin use; 2° a model including statin use and propensity scores (using a restricted cubic spline); 3° a model including statin use, propensity scores and all relevant variables mentioned above. Since the linearity assumption was deemed appropriate for all continuous variables in the model (p>0.1 for the assessment of linearity in the full model), the final model only included linear terms for all variables.
The baseline characteristics of the population are provided in tables 1 and 2. There was an equal distribution in gender (51.3% males) in the overall cohort. There was a high prevalence of metabolic syndrome (44.5%), diabetes (19.8%), current smokers (36.5%) and MAU (16.4%) in the overall cohort. ACE-I and/or ARB were the most commonly prescribed antihypertensive agents (55.9%). History of a cardiovascular event was recorded in 11.3% of the patients. Mean age of the cohort was 57.5±7.5 years. One third (30.8%) of the patients used a statin.
In univariable analysis, statin users were more likely to be male (p<0.001), had a higher frequency of metabolic syndrome (p<0.001), diabetes type 2 (p<0.001), MAU (p<0.001), ACE-i/ARB treatment (p<0.001), and previous cardiovascular events (p<0.001), were older (p<0.001), had larger BMI (p<0.001), lower diastolic blood pressure (p = 0.02), higher fasting glucose (p<0.001), serum uric acid (p = 0.004), and triglycerides (p = 0.003), had lower levels of LDL (p<0.001) and HDL cholesterol (p = 0.001) compared to patients not taking statins (tables 1 and 2). The univariable odds ratio of MAU in patients using vs. not using a statin was 2.01 (95% CI: 1.34–3.01, p = 0.0009, table 3A).
After multivariable analysis including the propensity score for statin use, the odds of MAU was still significantly higher in patients taking a statin (OR: 1.82, 95% CI: 1.14–2.91, p = 0.01, table 3B). When all other variables were forced into the model, use of statin still was independently associated with a higher odds of MAU (OR: 1.90, 95% CI: 1.15–3.11, p = 0.01, table 3C). Next to statin use, only diabetes (OR: 1.92, 95% CI: 1.00–3.66, p = 0.05) and smoking (OR: 1.49, 95% CI: 0.99–2.26, p = 0.06) were independently associated with MAU after adjusting for the likelihood of receiving a statin, suggesting that prescription of a statin overrides the association between cardiovascular risk factors, MAU and creates collinearity by acting as a surrogate.
Our data create concern on the use of MAU as a predictor or marker of cardiovascular or renal disease in cohorts with patients using statins. Statin use apparently could blur the interpretation of MAU by two potential mechanisms: 1° higher prevalence of MAU in patients using a statin, even after correction for bias by indication and 2° masking of cardiovascular risk factors in multivariable analyses, as statin use behaves as a surrogate for these markers. In epidemiological studies evaluating the association between cardiovascular risk factors and MAU, statin use can induce incorrect labeling of patients as having a cardiovascular or renal risk factor, and interpretation of other risk factors for cardiovascular or renal disease can be confounded by the way the use of statins is handled in the analysis. In this cross-sectional analysis, we observed a two-fold higher prevalence of MAU in subjects who use vs. those who do not use a statin. However, part of this association (figure S1) can be attributed to bias by indication, as patients are often prescribed statins because they have cardiovascular risk factors which are by themselves associated with enhanced risk for MAU. Indeed, we observed a higher prevalence of cardiovascular risk factors in patients taking vs. not taking a statin in our study. We tried to exclude this bias by indication by the use of a propensity score analysis. Adjusting for the propensity score allows to analyze the difference in occurrence of MAU between patients with a comparable propensity to receive a statin, while one group does whereas the other does not receive the drug. The technique of propensity score is well established to address confounding and bias by indication in observational studies , . However, this increased odds ratio remained present even after correcting for the fact that statins are usually prescribed in patients with cardiovascular risk factors which by themselves are associated with MAU, using the robust technique of propensity score. This observation can either be due to residual or unmeasured confounding or there can really be an induction of MAU by statin use (figure S1). Our data stress that statin use confounds the impact of the individual risk factors on MAU, as statin use behaves as a surrogate for presence of cardiovascular risk factors. As a consequence, in studies where MAU is either used as a marker or as a surrogate endpoint, the association between outcomes and certain cardiovascular risk factors can be blurred, and this in an unpredictable and variable fashion, depending upon the prevalence of statin use in the cohort. On the other hand, if statins really induce MAU, theoretically it can be both of glomerular or of tubular origin (figure S1). We did not find any publication, either human, animal or in vitro, indicating that statin associated proteinuria is of glomerular origin, but at least three in vitro or animal studies demonstrated that statins do inhibit tubular reabsorption of filtered albumin and in this way could generate MAU in a dose-dependent manner and in absence of cytotoxicity , , . There is also growing evidence that also in other conditions MAU can be the consequence of tubular dysfunction, even in presence of an entirely intact glomerulus , . One epidemiological study in humans also coined statin induced proteinuria as being tubular in origin, and even demonstrated a dose-effect relation with rosuvastatin . This would explain why statins fail to consistently result in reduction of MAU in subjects with low grade MAU, or why higher vs. lower doses of statin fail to further reduce MAU , , as the beneficial effect of statins on the glomerular MAU is counterbalanced by the induction of tubular MAU. It is very unlikely that statin induced MAU is associated with an increased cardiovascular risk, but its impact on the functional capacity and the morphological integrity of the kidneys is unknown. Even when the tubular albuminuria induced by statins is harmless , it interferes with the implication of MAU as predictor or marker of cardiovascular and renal risk by incorrectly labeling a subject as having a risk factor. Of note, this would imply that the prognostic impact of glomerular MAU (so not induced by statin use) in populations with a high prevalence of statin use, would be underestimated. The hypothesis that statin induced MAU is tubular in origin would also fit with the favorable effect of statins on cardiovascular disease and on progression of renal disease, as these effects are related to the reduction of glomerular MAU associated with the improvement of endothelial dysfunction , .
This cross-sectional study could not prove a causal connection between statin use and de novo MAU. Using the technique of propensity score we achieved “pseudo-randomization”, which in fact obviates the drawbacks imposed by the method of the study, but which is not free from unmeasured biases . Unfortunately, although dose dependency and a higher frequency of more potent inhibitors of HMG coA reductase could add further strength to the association with MAU, the prescribed daily dose and type of statin were as per protocol not registered in our study. Another limitation of our study is that MAU was measured in a single morning urine, whereas guidelines recommend to have at least two positive MAU in three consecutive first morning urine samples before labeling a person as having MAU . However, in view of the mechanism of inhibition of tubular endocytosis, it is unlikely that statin associated MAU would disappear by repeated testing, unless the statin would be stopped temporarily to confirm the diagnosis. Second, intermittent MAU should not be considered as a predictor or marker of cardiovascular or renal risk, as it is not linked to endothelial dysfunction . In line with this, we demonstrated in another cohort, that patients with intermittent MAU have far less cardiovascular risk factors as compared to patients with persisting MAU . Our study shows that, in addition to the problems caused by single vs. multiple sampling, the use of a statin can also lead to an in incorrect labeling of subject as having MAU.
The strength of this study is that it reflects routine clinical practice in hypertensive patients. To the best of our knowledge, this is the first study pointing to an independent association between statin use and MAU, even after correction for bias by indication by the use of a propensity score, underlining the potential consequences of confounding induced by statin use on the interpretation of MAU as a predictor or marker of cardiovascular or renal disease in epidemiological trials.
According to our data, statins are independently associated with an increased prevalence of MAU, even after correction for bias by indication. As this MAU is most likely of tubular origin, it is uncertain and rather unlikely whether it has the same prognostic impact for renal and cardiovascular disease as endothelial dysfunction induced glomerular MAU. As such, it can lead to incorrect labeling of subjects as having a cardiovascular risk factor.
Flow chart of hypotheses to explain the observation of higher prevalence of MAU in statin users. MAU: microalbuminuria, OR: odds ratio, CI: confidence interval.
List of missing data per variable. ARB: angiotensin receptor blocker; ACE-I: angiotensin converting enzyme inhibitor.
Comparison of Baseline Characteristics Adjusted for Propensity Scores. MS: metabolic syndrome; CV event: cardiovascular event; ARB: angiotensin receptor blocker; ACE-I: angiotensin converting enzyme inhibitor.
We thank the steering committee members: JM Billiouw, M Couttenye, J Donck, M Dratwa, A Dufour, B Georges, M Henckes, M Jadoul, E. Lessafre, JM Krzesinski, N Lameire, P Leenaerts, R Lins, Y Pirson, JC Stolear, C Tielemans, W Van Biesen, R Vanholder, Y Vanrenterghem, D Verbeelen, G Verpooten and the investigators: F Bare, A Bernaers, I Bijnens, P Blondeel, L Bonami, L Bostoen, N Boussemaere, I Buntinx, D Chevalier, A Cleys, H Cuypers, G D'Hont, E De Ganck, J De Jaeger, A De Leeuw, K De Praeter, K De Schutter, JL Delattre, P Delhaye, A Delvosalle, A Demeester, B Dewaele, M Dooms, B Englebienne, L Erpicum, P Feys, H Flamee, R Follet, J Galot, K Geens, W Geerts, C Gilio, P Govaert, J Helincks, K Hendrickx, Y Henoumont, G Hoogmartens, S Hoppenbrouwers, J Ingelaere, S Konings, G Lannoo, R Leuridan, M Lootens, J Luyts, D Mebis, J Mestdagh, L Meyvis, B Morelle, D Mulkers, M Nevelsteen, F Nollomont, L Phang, A Pollet, E Pycke, V Rémy, M Rombouts, P Schleich, E Schoofs, H Symons, C Tack, L Tanghe, J Van Assche, J Van Boxem, O Van Damme, E Van der Putte, H Van der Stockt, J Van Massenhove, N Van Mulders, M Vande Voorde, D Vanmansart, J Vermaete, J Vernijns, L Vernijns, B Verstraete, A Villé, E Willekens, S Delville, M Deroubaix, M Ferro, M Ghesquiere, L Rouvroy, P Soetaert, N Van Nieuwenhuyse, E Vanden Eynde.
Conceived and designed the experiments: AvdT WVB SVL. Performed the experiments: AvdT WVB. Analyzed the data: AvdT WVB KB. Contributed reagents/materials/analysis tools: KDL HW. Wrote the paper: AvdT WVB RV.
- 1. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, et al. (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421–426.
- 2. Hallan H, Romundstad S, Kvenild K, Holmen J (2003) Microalbuminuria in diabetic and hypertensive patients and the general population - Consequences of various diagnostic criteria - The Nord-Trondelag Health Study (HUNT). Scandinavian Journal of Urology and Nephrology 37: 151–158.
- 3. Klausen KP, Scharling H, Jensen G, Jensen JS (2005) New definition of microalbuminuria in hypertensive subjects - Association with incident coronary heart disease and death. Hypertension 46: 33–37.
- 4. van der Tol A, Van Biesen W, Verbeke F, De Groote G, Vermeiren F, et al. (2010) Towards a rational screening strategy for albuminuria: results from the unreferred renal insufficiency trial. PloS one 5:
- 5. Bigazzi R, Bianchi S, Baldari D, Campese VM (1998) Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. Journal of Hypertension 16: 1325–1333.
- 6. Mogensen CE (1999) Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42: 263–285.
- 7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.
- 8. Douglas K, O'Malley PG, Jackson JL (2006) Meta-analysis: the effect of statins on albuminuria. Annals of internal medicine 145: 117–124.
- 9. Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. Journal of the American Society of Nephrology: JASN 17: 2006–2016.
- 10. Fried LF, Orchard TJ, Kasiske BL (2001) Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney International 59: 260–269.
- 11. Verhulst A, D'Haese PC, De Broe ME (2004) Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. Journal of the American Society of Nephrology: JASN 15: 2249–2257.
- 12. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, et al. (2004) Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. Journal of the American Society of Nephrology: JASN 15: 2258–2265.
- 13. van Zyl-Smit R, Firth JC, Duffield M, Marais AD (2004) Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 19: 3176–3179.
- 14. Wolfe SM (2004) Dangers of rosuvastatin identified before and after FDA approval. Lancet 363: 2189–2190.
- 15. Deslypere JP, Delanghe J, Vermeulen A (1990) Proteinuria as Complication of Simvastatin Treatment. Lancet 336: 1453–1453.
- 16. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, et al. (2006) The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation 21: 3106–3114.
- 17. Rubin DB (1987) multiple imputation for nonrespons in surveys. New York: John Wiley & Sons.
- 18. Frank EH (2009) Hmisc: Harrell Miscerllaneous. R package version 3.7-0.
- 19. Cleeman JI, Grundy SM, Becker D, Clark LT, Cooper RS, et al. (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama-Journal of the American Medical Association 285: 2486–2497.
- 20. The R project for statistical computing. Available: http://www.R-project.org. Accessed 2012 Jan 18.
- 21. Heinze G, Juni P (2011) An overview of the objectives of and the approaches to propensity score analyses. European heart journal.
- 22. Zhehui L, Gardiner JC, Bradley CJ (2010) Applying propensity score methods in medical research: pitfalls and prospects. Medical care research and review: MCRR 67: 528–554.
- 23. Barnieh L, James MT, Zhang J, Hemmelgarn BR (2011) Propensity score methods and their application in nephrology research. Journal of nephrology.
- 24. Rosenbaum PR, Rubin DB (1983) The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika 70: 41–55.
- 25. Corna D, Sangalli F, Cattaneo D, Carrara F, Gaspari F, et al. (2007) Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. American Journal of Nephrology 27: 630–638.
- 26. Pollock CA, Poronnik P (2007) Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Current opinion in nephrology and hypertension 16: 359–364.
- 27. Jefferson JA, Shankland SJ, Pichler RH (2008) Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney International 74: 22–36.
- 28. Kostapanos MS, Milionis HJ, Saougos VG, Lagos KG, Christine K, et al. (2007) Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. Journal of cardiovascular pharmacology and therapeutics 12: 292–297.
- 29. Sorof J, Berne C, Siewert-Delle A, Jorgensen L, Sager P, et al. (2006) Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Research and Clinical Practice 72: 81–87.
- 30. Rutter MK, Prais HR, Charlton-Menys V, Gittins M, Roberts C, et al. (2011) Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabetic Medicine 28: 100–108.
- 31. FDA Public Health Advisory for Crestor (Rosuvastatin). Available: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM051756. Accessed 2012 Jan 18.
- 32. Knight SF, Yuan J, Roy S, Imig JD (2010) Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. American journal of physiology Renal physiology 298: F86–94.
- 33. Park JK, Mervaala EM, Muller DN, Menne J, Fiebeler A, et al. (2009) Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. Journal of Hypertension 27: 599–605.
- 34. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease, guidelines 5. Assesment of proteinuria. Available: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p5_lab_g5.htm. Accessed 2012 Jan 18.
- 35. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H (2003) Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. American Journal of Kidney Diseases 42: 466–473.
- 36. Van der Tol A, Van Biesen W, De Groote G, Verbeke P, Vermeiren F, et al. (2011) Mislabeling Cardiovascular Risk by One Single Measurement of Microalbuminuria. Acta Clinica Belgica 66: 171–171.